Revista do Colégio Brasileiro de Cirurgiões
http://www.rcbc.periodikos.com.br/article/doi/10.1590/0100-6991e-2026002925
Revista do Colégio Brasileiro de Cirurgiões
Artigo Original

Expressão hepatocitária do Fator Inibitório da Migração de Macrófagos (MIF) está associada à lesão de isquemia-reperfusão após transplante hepático

Hepatocellular Expression of Macrophage Migration Inhibitory Factor (MIF) Is Associated with Ischemia-Reperfusion Injury After Liver Transplantation

Rodrigo Humberto Vilar Pontes Filho; Camila Xavier Brito; Serena Dáfne do Carmo Silva; Agnaldo Soares Lima; Francisco Guilherme Cancela e Penna; Fernanda Maria Farage Osório; Níkolas Knupp Thome; Cristiano Xavier Lima; Paula Vieira Teixeira Vidigal

http://dx.doi.org/10.1590/0100-6991e-2026002925 RCBC, vol.53, e2026002925, 2026
PDF Português
PDF English
SciELO
Downloads: 0
Views: 34

Resumo

Introdução: A lesão de isquemia-reperfusão (LIR) é um evento determinante da função inicial do enxerto após o transplante hepático (TH). O fator inibitório da migração de macrófagos (MIF) é uma citocina pleiotrópica envolvida em vias inflamatórias e em mecanismos de adaptação celular ao estresse oxidativo. Embora possa exercer papel modulador na LIR, sua expressão tecidual imediata em enxertos hepáticos permanece pouco caracterizada.

Métodos: Este estudo retrospectivo avaliou receptores adultos submetidos a transplante hepático, com análise histológica e imuno-histoquímica de biópsias obtidas após a reperfusão. A expressão de MIF foi quantificada por meio do plugin IHC Profiler (ImageJ), enquanto a LIR foi graduada segundo critérios histopatológicos validados.

Resultados: Entre 153 biópsias analisadas, 103 preencheram os critérios de elegibilidade, com predomínio de LIR ausente ou leve (70,9%). A expressão hepatocitária de MIF foi predominantemente fraca ou moderada. Marcações mais intensas de MIF associaram-se a menor gravidade da LIR (p < 0,05). A expressão de MIF correlacionou-se com parâmetros laboratoriais pré-transplante, sem associação com esteatose ou com desfechos precoces, incluindo retransplante ou óbito em até 15 dias.

Conclusão: Esses achados sugerem que maior marcação tecidual de MIF no momento da reperfusão relaciona-se a menor intensidade da LIR, indicando possível papel adaptativo dessa citocina nessa fase crítica. O MIF desponta como potencial marcador tecidual complementar ao escore histopatológico tradicional, com relevância para a avaliação de enxertos e para o desenvolvimento de estratégias contemporâneas de perfusão hepática.

Palavras-chave

Transplante de Fígado; Lesão por Isquemia-Reperfusão; Fator Inibidor da Migração de Macrófago  

Abstract

Introduction: Ischemia-reperfusion injury (IRI) is a major determinant of initial graft function after liver transplantation (LT), directly influencing the incidence of early dysfunction and short-term clinical outcomes. Macrophage migration inhibitory factor (MIF), a pleiotropic cytokine involved in inflammatory pathways and mechanisms of cellular adaptation to oxidative stress, may play a modulatory role in IRI, although its immediate tissue behaviour in grafts remains poorly characterised.

Methods: We retrospectively evaluated adult LT recipients who underwent post-reperfusion biopsies suitable for histological and immunohistochemical analysis. Immunohistochemical expression of MIF was quantified using the IHC Profiler plugin (ImageJ), whereas IRI was graded according to validated histopathological criteria.

Results: Among 153 biopsies analysed, 103 met the eligibility criteria, with most cases showing absent or mild IRI (70.9%). Hepatocellular expression of MIF was predominantly weak or moderate. Stronger immunohistochemical staining for MIF was associated with lower IRI severity (p<0.05). MIF expression correlated with pre-transplant laboratory parameters, without association with steatosis or early outcomes, including retransplantation or death within 15 days.

Conclusion: The findings suggest that greater immunohistochemical expression of MIF at reperfusion is associated with lower IRI intensity, indicating a possible adaptive role for this cytokine during this critical phase. MIF emerges as a potential tissue marker complementary to traditional histopathological scoring, with relevance for graft assessment and use in contemporary liver perfusion strategies.

Keywords

Liver Transplantation; Reperfusion Injury; Immunohistochemistry; Macrophage Migration Inhibitory Factors  

Referências

1 Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675-88. doi: 10.1016/j.jhep.2012.04.015.

2 Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10(2):79-89. doi: 10.1038/nrgastro.2012.225.

3 Hann A, Osei-Bordom DC, Neil DAH, Ronca V, Warner S, Perera MTPR. The Human Immune Response to Cadaveric and Living Donor Liver Allografts. Front Immunol. 2020;11:1227. doi: 10.3389/fimmu.2020.01227.

4 Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-9. doi: 10.1002/lt.22091.

5 Ito T, Naini BV, Markovic D, Aziz A, Younan S, Lu M, et al. Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients. Am J Transplant. 2021;21(2):614-25. doi: 10.1111/ajt.16219.

6 Fuentes-Valenzuela E, Tejedor-Tejada J, García-Pajares F, Rubiales BM, Nájera-Muñoz R, Maroto-Martín C, et al. Postreperfusion liver biopsy as predictor of early graft dysfunction and survival after orthotopic liver transplantation. J Clin Exp Hepatol. 2022;12(4):1133-41. doi: 10.1016/j.jceh.2021.12.015.

7 Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF Signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11):1467-76. doi: 10.1084/jem.20030286.

8 Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791-800. doi: 10.1038/nri1200.

9 Kang I, Bucala R. The immunobiology of MIF: function, genetics and prospects for precision medicine. Nat Rev Rheumatol. 2019;15(7):427-37. doi: 10.1038/s41584-019-0238-2.

10 Sumaiya K, Langford D, Natarajaseenivasan K, Shanmughapriya S. Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther. 2022;233:108024. doi: 10.1016/j.pharmthera.2021.108024.

11 Herkens L, Droste P, Boor P. The multifaced role of the macrophage migration inhibitory factor family in organ fibrosis. Am J Physiol-Cell Physiol. 2025;329(1):C119-35. doi: 10.1152/ajpcell.00198.2025.

12 Ohkawara T, Nishihira J, Takeda H, Asaka M, Sugiyama T. Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J Gastroenterol. 2005;40(2):117-22. doi: 10.1007/s00535-004-1526-3.

13 Ministério da Saúde (Brasil). Portaria no 2.600, de 21 de outubro de 2009. Aprova o Regulamento Técnico do Sistema Nacional de Transplantes. Brasília, DF: Ministério da Saúde; 2009.

14 Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A Model to Predict Survival in Patients With End-Stage Liver Disease. Hepatology. 2001;33(2):464-70. doi: 10.1053/jhep.2001.22172.

15 Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl. 2001;7(7):567-80. doi: 10.1053/jlts.2001.25879.

16 Ali JM, Davies SE, Brais RJ, Randle LV, Klinck JR, Allison MED, et al. Analysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomes. Liver Transpl. 2015;21(4):487-99. doi: 10.1002/lt.24072.

17 Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature. 2008;451(7178):578-82. doi: 10.1038/nature06504.

18 Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated Hepatic co-morbidities: a comprehensive review of human and rodent studies. Front Immunol. 2015;6:308. doi: 10.3389/fimmu.2015.00308.

19 Zhang X, Fan L, Wu J, Xu H, Leung WY, Fu K, et al. Macrophage p38a promotes nutritional steatohepatitis through M1 polarization. J Hepatol. 2019;71(1):163-74. doi: 10.1016/j.jhep.2020.06.019.

20 Ruze A, Chen BD, Liu F, Chen XC, Gai MT, Li XM, et al. Macrophage migration inhibitory factor plays an essential role in ischemic preconditioning-mediated cardioprotection. Clin Sci. 2019;133(5):665-80. doi: 10.1042/CS20181013.

21 El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E, et al. An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis. Nat Commun. 2025;16(1):2297. doi: 10.1038/s41467-025-57540-z.

22 Liu A, Fang H, Dirsch O, Jin H, Dahmen U. Early release of macrophage migration inhibitory factor after liver ischemia and reperfusion injury in rats. Cytokine. 2012;57(1):150-7. doi: 10.1016/j.cyto.2011.11.009.

23 Emontzpohl C, Stoppe C, Theißen A, Beckers C, Neumann UP, Lurje G, et al. The role of macrophage migration inhibitory factor in remote ischemic conditioning induced hepatoprotection in a rodent model of liver transplantation. Shock. 2019;52(5):e124-34. doi: 10.1097/SHK.0000000000001307.

24 Chen Z, Zhang J, Zhang L, Liu Y, Zhang T, Sang X, et al. Identification of PANoptosis related biomarkers to predict hepatic ischemia-reperfusion injury after liver transplantation. Sci Rep. 2025;15(1):15437. doi: 10.1038/s41598-025-99264-6.

25 Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol. 1997;150(1):235-46.

26 Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, et al. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol. 2003;162(1):47-56. doi: 10.1016/S0002-9440(10)63797-2.

27 Pohl J, Hendgen-Cotta UR, Rammos C, Luedike P, Mull E, Stoppe C, et al. Targeted intracellular accumulation of macrophage migration inhibitory factor in the reperfused heart mediates cardioprotection. Thromb Haemost. 2016;115(01):200-12. doi: 10.1160/TH15-05-0436.

28 Baron-Stefaniak J, Schiefer J, Miller EJ, Plöchl W, Krenn CG, Berlakovich GA, et al. Graft-derived macrophage migration inhibitory factor correlates with hepatocellular injury in patients undergoing liver transplantation. Clin Transplant. 2017;31(6):e12982. doi: 10.1111/ctr.12982.
 

 

Submetido em:
22/09/2025

Aceito em:
05/05/2026

6a739fa4a9539532716a8895 rcbc Articles
1809-4546 (Eletrônico) 0100-6991 (Impresso)
RCBC ©2026 Todos os direitos reservados sobre o conteúdo deste website. Os artigos seguem suas próprias licenças.

RCBC

Share this page
Page Sections